Back to Melanotan-ii research
melanotan-ii melanocortin agonist preclinical animal n preclinical 2026-04-03 PubMed

Melanotan II's thermogenic effects are mediated by CB1 receptors in the PVH of male rats

The PVH as a site of CB1-mediated stimulation of thermogenesis by MC4R agonism in male rats.

Background

The melanocortin system is a critical regulator of energy balance, with the MC4R receptor playing a key role in appetite and energy expenditure. Agonists of this receptor, like Melanotan II, are known to increase thermogenesis, particularly in brown adipose tissue (BAT), which burns fat to produce heat. However, the precise neural circuits and interacting pathways are not fully understood. Separately, the endocannabinoid system, via the CB1 receptor, is known to influence energy metabolism, often promoting energy storage. Understanding how these two powerful systems interact, specifically within key brain regions like the paraventricular hypothalamic nucleus (PVH), could reveal novel mechanisms for controlling metabolic rate and body temperature, a crucial aspect of metabolic health and disease.

Study Design

The study used male rats to investigate the interaction between MC4R and CB1 systems. In the first experiment, rats received infusions of the MC4R agonist Melanotan II (MTII) into the third brain ventricle, along with either the CB1 agonist δ(9)-THC or the CB1 antagonist AM251. Researchers measured whole-body thermogenesis via indirect calorimetry and brown adipose tissue (BAT) thermogenesis by tracking interscapular BAT (iBAT) temperature. They also assessed fatty acid and glucose uptake in iBAT using (14)C-bromopalmitate and (3)H-deoxyglucose tracers. A second experiment localized the effect by infusing MTII directly into the paraventricular hypothalamic nucleus (PVH) while infusing δ(9)-THC or AM251 into the fourth ventricle.

Results

Activating MC4R with MTII significantly stimulated whole-body energy expenditure and increased iBAT temperature. This effect was directly opposed by the CB1 system. The CB1 agonist δ(9)-THC blunted MTII's effects on both energy expenditure and iBAT temperature, whereas the CB1 antagonist AM251 tended to potentiate them. Further analysis showed that δ(9)-THC also blocked the MTII-induced increase in fatty acid ((14)C-bromopalmitate) and glucose ((3)H-deoxyglucose) uptake into iBAT.

Critically, δ(9)-THC also attenuated the stimulating effect of MTII on the expression of key thermogenic genes in iBAT, including Pgc1α, Dio2, Cpt1b, and Ucp1. When MTII was infused directly into the PVH, subsequent administration of δ(9)-THC still blunted the rise in iBAT temperature and blocked the increase in (14)C-bromopalmitate uptake and Pgc1α and Dio2 gene expression. This demonstrates that the paraventricular nucleus of the hypothalamus (PVH) is a key site for this CB1-mediated modulation of melanocortin-driven thermogenesis.

Key Findings

  • The CB1 agonist δ(9)-THC blunted the stimulating effects of Melanotan II on both whole-body energy expenditure and iBAT temperature.
  • The CB1 antagonist AM251 showed a tendency to potentiate the thermogenic effects of Melanotan II.
  • δ(9)-THC blocked MTII-induced uptake of (14)C-bromopalmitate (fatty acids) and (3)H-deoxyglucose (glucose) in brown adipose tissue.
  • MTII's stimulation of key thermogenic genes (Pgc1α, Dio2, Cpt1b, Ucp1) in iBAT was attenuated by δ(9)-THC.
  • Infusing MTII into the PVH and δ(9)-THC into the fourth ventricle demonstrated that the PVH is a key site for this interaction.

Why It Matters

This research clarifies a direct conflict between the melanocortin and cannabinoid systems in regulating thermogenesis, pinpointing the PVH as a central hub for this interaction. For peptide users, this suggests that concurrent use of cannabinoids (like THC) could significantly blunt or even negate the fat-burning and metabolic-boosting effects of Melanotan II. To maximize the thermogenic benefits of MTII, avoiding CB1 agonists may be necessary. From a therapeutic standpoint, this finding opens up new possibilities for developing more targeted metabolic drugs. By understanding that CB1 signaling can override MC4R-induced energy expenditure, future protocols could involve co-administering CB1 antagonists with MC4R agonists to potentially enhance weight loss and metabolic rate. The study provides a strong rationale for investigating this combined therapeutic strategy, though human clinical trials are still a distant prospect.


melanotan-ii melanocortin agonist mc4r-agonist cb1-agonist cb1-antagonist
Source: pubmed:24949658 · Ingested Apr 3, 2026 · Digest: gemini-2.5-pro